WHO ICTRP trial
Combination of Atazanavir and Raltegravir as Dual Strategy - CARDS STUDY
EUCTR2009-014656-30-IT · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2009-014656-30-IT |
|---|---|
| Public title | Combination of Atazanavir and Raltegravir as Dual Strategy - CARDS STUDY |
| Scientific title | Combination of Atazanavir and Raltegravir as Dual Strategy - CARDS STUDY |
| Primary sponsor | AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" (A.O. DI RILIEVO NAZIONALE) |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Italy |
| Conditions | Documented HIV infection |
| Interventions | Trade Name: ISENTRESS Pharmaceutical Form: Coated tablet INN or Proposed INN: Raltegravir Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- Trade Name: REYATAZ Pharmaceutical Form: Capsule, hard INN or… |
| Registration date | Jul 24, 2009 |
| Secondary IDs | CARDS Study |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: